OBJECTIVE: We test the hypothesis that racial or ethnic differences exist in relapse rates to fluoxetine discontinuation in major depressive disorder (MDD). METHOD: Data are from a prospective study examining the relapse rates secondary to fluoxetine discontinuation in MDD. Subjects in the discontinuation phase consisted of 255 adults aged18 to 65: 214 subjects who self-identified as white, 22 as African American, 13 as Latino American, and 6 as Asian American. RESULTS: In both the fluoxetine and placebo groups, no statistically significant differences emerged when comparing time to relapse for minority groups as compared to the white population. Adjusting for statistically significant predictors of relapse (symptom severity, neurovegetative symptom pattern, sex) and for educational level did not change the outcome of the survival analyses. CONCLUSIONS: Although the size of minority groups in this sample was modest, in a randomized, controlled trial setting, minority and white patients may have similar rates of relapse in MDD. This finding reinforces the importance of maintenance treatment in relapse for both minority as well as white patients with MDD. Given the self-selecting nature of clinical trials, future studies are needed to further examine the potential influence of underlying cultural factors on clinical outcomes in minority populations.
RCT Entities:
OBJECTIVE: We test the hypothesis that racial or ethnic differences exist in relapse rates to fluoxetine discontinuation in major depressive disorder (MDD). METHOD: Data are from a prospective study examining the relapse rates secondary to fluoxetine discontinuation in MDD. Subjects in the discontinuation phase consisted of 255 adults aged 18 to 65: 214 subjects who self-identified as white, 22 as African American, 13 as Latino American, and 6 as Asian American. RESULTS: In both the fluoxetine and placebo groups, no statistically significant differences emerged when comparing time to relapse for minority groups as compared to the white population. Adjusting for statistically significant predictors of relapse (symptom severity, neurovegetative symptom pattern, sex) and for educational level did not change the outcome of the survival analyses. CONCLUSIONS: Although the size of minority groups in this sample was modest, in a randomized, controlled trial setting, minority and white patients may have similar rates of relapse in MDD. This finding reinforces the importance of maintenance treatment in relapse for both minority as well as white patients with MDD. Given the self-selecting nature of clinical trials, future studies are needed to further examine the potential influence of underlying cultural factors on clinical outcomes in minority populations.
Authors: J F Wilson; M E Weale; A C Smith; F Gratrix; B Fletcher; M G Thomas; N Bradman; D B Goldstein Journal: Nat Genet Date: 2001-11 Impact factor: 38.330
Authors: Lisa A Cooper; Junius J Gonzales; Joseph J Gallo; Kathryn M Rost; Lisa S Meredith; Lisa V Rubenstein; Nae-Yuh Wang; Daniel E Ford Journal: Med Care Date: 2003-04 Impact factor: 2.983
Authors: Ira M Lesser; Daniel B Castro; Bradley N Gaynes; Jodi Gonzalez; A John Rush; Jonathan E Alpert; Madhukar Trivedi; James F Luther; Stephen R Wisniewski Journal: Med Care Date: 2007-11 Impact factor: 2.983
Authors: Henrik Walter; Quentin J M Huys; Isabel M Berwian; Julia G Wenzel; Leonie Kuehn; Inga Schnuerer; Erich Seifritz; Klaas E Stephan Journal: Sci Rep Date: 2022-07-01 Impact factor: 4.996